Eli Wallace, BridgeBio Oncology Therapeutics CEO
BridgeBio spins out oncology unit with $200M in backing for RAS assets
BridgeBio, a biotech known for its model of setting up subsidiaries to house its R&D programs, is splitting off its oncology unit with $200 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
